NCT03942926

The Efficacy and Safety of Sirolimus for Plastic Bronchitis

The Efficacy and Safety of Sirolimus for Plastic Bronchitis：a Pilot Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 13 Years
• Healthy volunteers: Not accepted

Summary

There is no confirmed drug therapy for plastic bronchitis. The study wish to test the effectiveness and safety of sirolimus (rapamycin) in patients with lymphatic plastic bronchitis.

Detailed description

Plastic bronchitis is a rare respiratory disorder characterized by formation of gelatinous or rigid cast of bronchial tree. Confirmed drug therapy for plastic bronchitis is lacking. Recently, part of plastic bronchitis has been found to have dysfunction of lymphatic circulation in the lung. Pulmonary lymphatic perfusion syndrome (PLPS) is regarded as a major mechanism of lymphatic plastic bronchitis. Sirolimus (rapamycin) has not been studied in plastic bronchitis, however, it has been shown effective in several lymphatic disorders, such as lymphangioleiomyomatosis, generalized lymphatic anomaly (GLA) including lymphangiomatosis, etc. We wish to test the effectiveness of sirolimus in lymphatic plastic bronchitis.

Conditions

• Plastic Bronchitis

Interventions

Type	Name	Description
DRUG	Sirolimus	Patients will receive sirolimus for 6 months.

Timeline

• Start date: 2019-05-06
• Primary completion: 2020-05-05
• Completion: 2020-05-05
• First posted: 2019-05-08
• Last updated: 2019-05-10

Locations

1 site across 1 country: China